Biotech Company Bioquark received an appropriate ethical permission from Institutional Review board at the National Institutes of Health in the United States and India to start a groundbreaking new medical trial of attempting to regenerate the brains of dead people.

The new medical trial is called ReAnima Project and will employ brain stem cells will help in the rebooting process in which brain cells can regenerate on their own. The process is similar to how certain kinds of reptiles and marine organisms can regenerate lost limbs. However, the trial does not expect to bring people back to life but to offer a proof if the idea is feasible.

Like Us on Facebook

The American biotech company will recruit 20 patients who are declared clinically dead from traumatic brain injury. The patients’ brains will be monitored for signs of regeneration, particularly in the upper spinal cord, the region where independent breathing and heartbeat are controlled.

The trial will engage the use of multiple procedures and therapies in an effort to revive the brains of those being kept alive solely through life support. Stem cells will be injected directly into the brain, along with a combination of peptides. In addition, lasers and other nerve stimulation techniques will be applied to the brain stem.

“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative (central nervous system) conditions, including Alzheimer’s and Parkinson’s disease,” said Dr. Sergei Paylian, the founder, president and chief science officer of Bioquark, in a statement.

Bioquark CEO Ira Pastor said that the company is looking forward to start the trial. They are keen into explore delve into an area of scientific understanding previously inaccessible with existing technologies. He added that ReAnima Project is really possible because of the join forces of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation.

Pastor hopes that the company will be able to report results within the first two to three months. ReAnima Project may have an impact in the future that may lead to the therapeutic developments connected with extreme disorders of consciousness such as minimally conscious, vegetative states and coma and a host of degenerative CNS conditions, including Parkinson's disease and Alzheimer's.

TagsBiotech Company, Bioquark, ReAnima Project, brain stem cells, dead ressurect, brain death, ressurect brain, dead back to life